138 related articles for article (PubMed ID: 3153245)
21. [Pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia--interindividual and intraindividual variations].
Hijiya N; Kato Y; Matsushita T; Yokoyama T
Rinsho Ketsueki; 1989 Nov; 30(11):1931-6. PubMed ID: 2607612
[TBL] [Abstract][Full Text] [Related]
22. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
23. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
[TBL] [Abstract][Full Text] [Related]
24. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity.
Hayder S; Lafolie P; Björk O; Peterson C
Ther Drug Monit; 1989 Nov; 11(6):617-22. PubMed ID: 2595740
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
[TBL] [Abstract][Full Text] [Related]
26. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Br J Clin Pharmacol; 2001 Jun; 51(6):531-9. PubMed ID: 11422012
[TBL] [Abstract][Full Text] [Related]
27. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.
Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R
Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306
[TBL] [Abstract][Full Text] [Related]
28. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
Lilleyman JS
Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
[No Abstract] [Full Text] [Related]
29. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
30. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.
Bhatia S; Landier W; Shangguan M; Hageman L; Schaible AN; Carter AR; Hanby CL; Leisenring W; Yasui Y; Kornegay NM; Mascarenhas L; Ritchey AK; Casillas JN; Dickens DS; Meza J; Carroll WL; Relling MV; Wong FL
J Clin Oncol; 2012 Jun; 30(17):2094-101. PubMed ID: 22564992
[TBL] [Abstract][Full Text] [Related]
31. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
32. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
33. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
[TBL] [Abstract][Full Text] [Related]
34. The pharmacology of orally administered chemotherapy. A reappraisal.
Poplack DG; Balis FM; Zimm S
Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
[TBL] [Abstract][Full Text] [Related]
35. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
36. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
Davies HA; Lilleyman JS
Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
[No Abstract] [Full Text] [Related]
37. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
[TBL] [Abstract][Full Text] [Related]
38. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
Ma XL; Wang B; Guo HY; Zhang YH; Zhu GH; Duan YL; Yang J; Zhang DW; Jin L; Zhang R; Zhang L; Xie J; Wu MY
Zhonghua Er Ke Za Zhi; 2010 Apr; 48(4):289-92. PubMed ID: 20654019
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
Tolbert JA; Bai S; Abdel-Rahman SM; August KJ; Weir SJ; Kearns GL; Neville KA
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28295989
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.
Zimm S; Collins JM; O'Neill D; Chabner BA; Poplack DG
Clin Pharmacol Ther; 1983 Dec; 34(6):810-7. PubMed ID: 6580097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]